Post

@rnflex.bsky.social

In another instance of what can't GLP1 meds do? Reduce schizophrenia hospitalization risk? Caveats: Observational data only! Chaser? Eli Lilly has a RCT studying a GIP/GLP1 dual agonist in schizophrenia right now. So we'll find out soon if this is real.

thelancet.comGLP-1 receptor agonist initiation and risk of psychiatric hospitalisation and emergency department presentation in adults with schizophrenia and type 2 diabetes in the USA: an observational cohort stu...GLP-1-based therapy initiation was associated with lower psychiatric acute-care use than non-initiation and initiation of DPP-4 or SGLT2 inhibitors in adults with schizophrenia and type 2 diabetes. Po...

David W (aka Flex NP)

@rnflex.bsky.social

Double chaser? Most atypical antipsychotics used for schizophrenia cause weight gain, insulin resistance, worsening lipid profiles. A dual agonist drug would directly counter that improving their health as well. Link to the Lilly trial: trials.lilly.com/en-US/trial/...

15/10/26, 11:29 am0 reposts1 like

No replies yet.